Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 21, 2025 (1 years ago)

BENLYSTA (belimumab)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations; potential temperature excursions due to transit delays

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

BENLYSTA (belimumab) for injection, 400 mg/20 mL vial, Rx only, NDC 49401-102-01, GSK.

Affected NDC 49401-0102-01

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Benlysta
belimumab
NDC 49401-0102
400 mg/5mL Injection, Powder, Lyophilized, for Solution
Intravenous
GlaxoSmithKline LLC Rx
Recalling firm
Mckesson Medical-Surgical Inc. Corporate Office
NDC code
49401-102-01
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0540-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by Mckesson Medical-Surgical Inc. Corporate Office

All 2025 recalls
Class II · Moderate risk

Infuvite Adult

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 54643-5649-1 D-0401-2025
Class II · Moderate risk

Medroxyprogesterone Acetate Injectable Suspension

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55150-0330-01 D-0400-2025
Class II · Moderate risk

Evenity

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55513-880-02 D-0539-2025
Class II · Moderate risk

PROLIA (denosumab)

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55513-710-21 D-0538-2025

Other temperature excursion recalls from 2025

All temperature excursion recalls
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025